Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma-Reference-Cited by-同舟云学术

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

Published:2014-06-26 Issue:26 Volume:123 Page:4111-4119
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Fresquet Vicente¹,Rieger Melissa¹,Carolis Carlo²,García-Barchino Maria J.¹,Martinez-Climent Jose A.¹

Affiliation:

1. Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; and

2. Centre for Genomic Regulation and Pompeu Fabra University, Barcelona, Spain

Abstract

Key Points Acquired selective mutations in Bcl2 and BAX conferred resistance to ABT-199 in experimental models of lymphoma. Monitoring the potential development of such mutations in patients treated with ABT-199 is advised.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/26/4111/1377858/4111.pdf

Reference51 articles.

1. The Bcl2 family: regulators of the cellular life-or-death switch.;Cory;Nat Rev Cancer,2002

2. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy.;Labi;Cell Death Differ,2006

3. Cell death: critical control points.;Danial;Cell,2004

4. Targeting the B-cell lymphoma/leukemia 2 family in cancer.;Davids;J Clin Oncol,2012

5. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.;Vogler;Cell Death Differ,2009

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains;EMBO Reports;2024-07-24

2. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance;Nature Reviews Cancer;2024-07-24

3. Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma;Cancers;2024-06-03

4. Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges;Acta Pharmaceutica Sinica B;2024-06

5. Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed;Cancers;2024-05-25